OX40 agonists have been explored in mouse orthotopic pancreatic cancer models, along with the administration of anti-PD1 therapy, and they have led to a reduction in regulatory and exhausted T cells and the stimulation of memory CD4+ and CD8+ T cells and B cells, resulting in tumor eradication [280]. Here, CD4 is linked to pancreatic neoplasm.